Fennec Pharmaceuticals Inc. is a clinical-stage biotechnology company developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. STS as a protectant against the hearing loss often caused by platinum-based anti-cancer agents in children.Children undergoing chemotherapy are going through an extraordinarily challenging time and the loss of hearing only compounds the difficulty. Fennec Pharma hopes that Sodium Thiosulfate will allow these children to keep their hearing and prevent permanent disability.Preclinical and clinical studies conducted by OHSU and others have indicated that STS can effectively reduce the incidence of hearing loss caused by platinum-based anticancer agents.